Navamedic launches new generic drug

Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced the launch of a new generic pharmaceutical product. Since 2011 the Company has been building a portfolio of generic drugs in the Nordic and Benelux markets.

The product now being launched is Candesartan Aspen, which is a drug, used in the treatment of hypertension. Candesartan Aspen can replace Atacand®, AstraZeneca. The new generic drug will be introduced across Navamedic's key markets. Navamedic has been developing its portfolio of generic drugs over the last three years and expects to become a significant provider of generic drugs in the Nordic and Benelux markets over the next few years.

 For further information, please call Olof Milveden, CEO, telephone +46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).